Pharma’s Cutting Edge

Yesterday, I presented my overview of the US Supreme Court decision in Wyeth v Levine, to join the thousands of other overviews published online in the last couple of days.  Many of those commenting are focusing on the implications of the decision for consumers and lawyers.  You will find less commentary on the likely business [...]

March 6th, 2009 | Category: Drug Safety, FDA, Healthcare Delivery, Legislation, Product Quality, Public Perceptions | Leave a comment

When I reported on the implications of Riegel v Medtronic for device manufacturers in February of last year, I indicated that the related Wyeth v Levine case would have potentially farther reaching implications for the pharmaceutical industry.  Yesterday, the US Supreme Court issued its 6-3 opinion in the case.  Let’s have a look at the [...]

March 5th, 2009 | Category: Drug Safety, FDA, Healthcare Delivery, Legislation, Product Quality, Public Perceptions | Comments (1)

After I had fnished reading the recent Supreme Court decision in Riegel v. Medtronic and some news reports describing the supposed implications of the decision for pharma, I was confused.  Were the implications for pharma product liability cases broad and profound or narrow and limited?  Certainly, the upcoming Wyeth Supreme Court case will have its [...]

February 22nd, 2008 | Category: Legislation, Product Quality | Comments (2)

Avastin Distribution Change - Open Letter
I read today’s WSJ Health Blog on Avastin thinking that Genentech had appeased eye specialists by maintaining distribution of Avastin to compounding pharmacies, but after reading the above open letter, I’m confused about Genentech’s actions in the recent past and about what it’s planning to do in the near future.  [...]

October 30th, 2007 | Category: Drug Safety, Product Quality, Public Perceptions, Sales and Marketing | Leave a comment